174 related articles for article (PubMed ID: 22015595)
1. Ink4a/Arf loss promotes tumor recurrence following Ras inhibition.
Vanbrocklin MW; Robinson JP; Lastwika KJ; McKinney AJ; Gach HM; Holmen SL
Neuro Oncol; 2012 Jan; 14(1):34-42. PubMed ID: 22015595
[TBL] [Abstract][Full Text] [Related]
2. Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation.
Robinson JP; VanBrocklin MW; Guilbeault AR; Signorelli DL; Brandner S; Holmen SL
Oncogene; 2010 Jan; 29(3):335-44. PubMed ID: 19855433
[TBL] [Abstract][Full Text] [Related]
3. Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo.
Robinson JP; Vanbrocklin MW; Lastwika KJ; McKinney AJ; Brandner S; Holmen SL
Oncogene; 2011 Mar; 30(11):1341-50. PubMed ID: 21057530
[TBL] [Abstract][Full Text] [Related]
4. Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt.
Uhrbom L; Dai C; Celestino JC; Rosenblum MK; Fuller GN; Holland EC
Cancer Res; 2002 Oct; 62(19):5551-8. PubMed ID: 12359767
[TBL] [Abstract][Full Text] [Related]
5. Akt signaling accelerates tumor recurrence following ras inhibition in the context of ink4a/arf loss.
Robinson GL; Robinson JP; Lastwika KJ; Holmen SL; Vanbrocklin MW
Genes Cancer; 2013 Nov; 4(11-12):476-85. PubMed ID: 24386508
[TBL] [Abstract][Full Text] [Related]
6. IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas.
Moore LM; Holmes KM; Smith SM; Wu Y; Tchougounova E; Uhrbom L; Sawaya R; Bruner JM; Fuller GN; Zhang W
Proc Natl Acad Sci U S A; 2009 Sep; 106(39):16675-9. PubMed ID: 19805356
[TBL] [Abstract][Full Text] [Related]
7. Cell type-specific tumor suppression by Ink4a and Arf in Kras-induced mouse gliomagenesis.
Uhrbom L; Kastemar M; Johansson FK; Westermark B; Holland EC
Cancer Res; 2005 Mar; 65(6):2065-9. PubMed ID: 15781613
[TBL] [Abstract][Full Text] [Related]
8. The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas.
Calogero A; Arcella A; De Gregorio G; Porcellini A; Mercola D; Liu C; Lombari V; Zani M; Giannini G; Gagliardi FM; Caruso R; Gulino A; Frati L; Ragona G
Clin Cancer Res; 2001 Sep; 7(9):2788-96. PubMed ID: 11555594
[TBL] [Abstract][Full Text] [Related]
9. Constitutive activation of Raf-1 induces glioma formation in mice.
Lyustikman Y; Momota H; Pao W; Holland EC
Neoplasia; 2008 May; 10(5):501-10. PubMed ID: 18472967
[TBL] [Abstract][Full Text] [Related]
10. Tumor escape in a Wnt1-dependent mouse breast cancer model is enabled by p19Arf/p53 pathway lesions but not p16 Ink4a loss.
Debies MT; Gestl SA; Mathers JL; Mikse OR; Leonard TL; Moody SE; Chodosh LA; Cardiff RD; Gunther EJ
J Clin Invest; 2008 Jan; 118(1):51-63. PubMed ID: 18060046
[TBL] [Abstract][Full Text] [Related]
11. Rapid and robust transgenic high-grade glioma mouse models for therapy intervention studies.
de Vries NA; Bruggeman SW; Hulsman D; de Vries HI; Zevenhoven J; Buckle T; Hamans BC; Leenders WP; Beijnen JH; van Lohuizen M; Berns AJ; van Tellingen O
Clin Cancer Res; 2010 Jul; 16(13):3431-41. PubMed ID: 20472681
[TBL] [Abstract][Full Text] [Related]
12. Quantitative real-time PCR does not show selective targeting of p14(ARF) but concomitant inactivation of both p16(INK4A) and p14(ARF) in 105 human primary gliomas.
Labuhn M; Jones G; Speel EJ; Maier D; Zweifel C; Gratzl O; Van Meir EG; Hegi ME; Merlo A
Oncogene; 2001 Mar; 20(9):1103-9. PubMed ID: 11314047
[TBL] [Abstract][Full Text] [Related]
13. Gliomagenesis arising from Pten- and Ink4a/Arf-deficient neural progenitor cells is mediated by the p53-Fbxw7/Cdc4 pathway, which controls c-Myc.
Kim HS; Woolard K; Lai C; Bauer PO; Maric D; Song H; Li A; Kotliarova S; Zhang W; Fine HA
Cancer Res; 2012 Nov; 72(22):6065-75. PubMed ID: 22986743
[TBL] [Abstract][Full Text] [Related]
14. Mast cell accumulation in glioblastoma with a potential role for stem cell factor and chemokine CXCL12.
Põlajeva J; Sjösten AM; Lager N; Kastemar M; Waern I; Alafuzoff I; Smits A; Westermark B; Pejler G; Uhrbom L; Tchougounova E
PLoS One; 2011; 6(9):e25222. PubMed ID: 21949886
[TBL] [Abstract][Full Text] [Related]
15. No evidence of oncogenic KRAS mutations in squamous cell carcinomas of the anogenital tract and head and neck region independent of human papillomavirus and p16(INK4a) status.
Prigge ES; Urban K; Stiegler S; Müller M; Kloor M; Mai S; Ottstadt M; Lohr F; Wenz F; Wagner S; Wittekindt C; Klussmann JP; Hampl M; von Knebel Doeberitz M; Reuschenbach M
Hum Pathol; 2014 Nov; 45(11):2347-54. PubMed ID: 25257576
[TBL] [Abstract][Full Text] [Related]
16. Essential role for Ras signaling in glioblastoma maintenance.
Holmen SL; Williams BO
Cancer Res; 2005 Sep; 65(18):8250-5. PubMed ID: 16166301
[TBL] [Abstract][Full Text] [Related]
17. Activated K-ras and INK4a/Arf deficiency cooperate during the development of pancreatic cancer by activation of Notch and NF-κB signaling pathways.
Wang Z; Banerjee S; Ahmad A; Li Y; Azmi AS; Gunn JR; Kong D; Bao B; Ali S; Gao J; Mohammad RM; Miele L; Korc M; Sarkar FH
PLoS One; 2011; 6(6):e20537. PubMed ID: 21673986
[TBL] [Abstract][Full Text] [Related]
18. Activated K-Ras and INK4a/Arf deficiency promote aggressiveness of pancreatic cancer by induction of EMT consistent with cancer stem cell phenotype.
Wang Z; Ali S; Banerjee S; Bao B; Li Y; Azmi AS; Korc M; Sarkar FH
J Cell Physiol; 2013 Mar; 228(3):556-562. PubMed ID: 22806240
[TBL] [Abstract][Full Text] [Related]
19. Driver or passenger effects of augmented c-Myc and Cdc20 in gliomagenesis.
Ji P; Zhou X; Liu Q; Fuller GN; Phillips LM; Zhang W
Oncotarget; 2016 Apr; 7(17):23521-9. PubMed ID: 26993778
[TBL] [Abstract][Full Text] [Related]
20. Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma.
Bruggeman SW; Hulsman D; Tanger E; Buckle T; Blom M; Zevenhoven J; van Tellingen O; van Lohuizen M
Cancer Cell; 2007 Oct; 12(4):328-41. PubMed ID: 17936558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
